Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    "methodist hospital" | Open Studies | "B-cell Lymphomas" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells
2 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Interventions: Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
3 Recruiting Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Condition: Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Intervention: Drug: CUDC-907
4 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19
5 Recruiting A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Condition: Advanced Cancer
Intervention: Drug: INCB057643

Study has passed its completion date and status has not been verified in more than two years.